Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Notes Payables (2020 - 2024)

Aytu Biopharma (AYTU) has disclosed Notes Payables for 7 consecutive years, with $4.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Notes Payables rose 291.03% to $4.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $4.0 million, a 291.03% increase, with the full-year FY2024 number at $2.4 million, up 53.23% from a year prior.
  • Notes Payables was $4.0 million for Q4 2024 at Aytu Biopharma, down from $4.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $10.4 million in Q1 2023 to a low of $41318.0 in Q4 2020.
  • A 4-year average of $3.3 million and a median of $2.4 million in 2024 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: crashed 86.19% in 2023, then soared 291.03% in 2024.
  • Aytu Biopharma's Notes Payables stood at $41318.0 in 2020, then skyrocketed by 17880.06% to $7.4 million in 2022, then tumbled by 86.19% to $1.0 million in 2023, then skyrocketed by 291.03% to $4.0 million in 2024.
  • Per Business Quant, the three most recent readings for AYTU's Notes Payables are $4.0 million (Q4 2024), $4.3 million (Q3 2024), and $2.4 million (Q2 2024).